Oncology Institute (NASDAQ:TOI) Trading 7.3% Higher - What's Next?

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report)'s share price rose 7.3% on Tuesday . The stock traded as high as $2.26 and last traded at $2.20. Approximately 2,172,953 shares changed hands during trading, an increase of 96% from the average daily volume of 1,111,021 shares. The stock had previously closed at $2.05.

Wall Street Analyst Weigh In

Separately, BTIG Research initiated coverage on Oncology Institute in a research report on Thursday, May 15th. They set a "buy" rating and a $7.00 price target for the company.

Oncology Institute Stock Up 1.0%

The company has a debt-to-equity ratio of 14.58, a current ratio of 1.79 and a quick ratio of 1.59. The firm has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $1.57. The company has a market cap of $219.95 million, a PE ratio of -3.52 and a beta of 0.02.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative return on equity of 445.02% and a negative net margin of 15.38%.

Insider Buying and Selling at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 76,324 shares of the firm's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $3.05, for a total transaction of $232,788.20. Following the sale, the director owned 1,272,724 shares in the company, valued at $3,881,808.20. This trade represents a 5.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brad Hively sold 1,976,137 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total value of $5,671,513.19. Following the sale, the director owned 603,501 shares in the company, valued at $1,732,047.87. This trade represents a 76.61% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,726,137 shares of company stock worth $13,379,013 in the last 90 days. Insiders own 8.50% of the company's stock.

Institutional Investors Weigh In On Oncology Institute

Hedge funds have recently made changes to their positions in the business. Josh Arnold Investment Consultant LLC acquired a new position in Oncology Institute in the first quarter valued at $2,267,000. FreeGulliver LLC boosted its holdings in Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock valued at $186,000 after acquiring an additional 412,578 shares during the last quarter. Virtu Financial LLC acquired a new position in Oncology Institute in the fourth quarter valued at $41,000. Goldman Sachs Group Inc. acquired a new position in Oncology Institute in the first quarter valued at $131,000. Finally, Jane Street Group LLC boosted its holdings in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after acquiring an additional 109,769 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company's stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.